Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIREBIOT trial of MBK-01 for recurrent diverticulitis
2023-506224-87-00Phase 2Authorised
- Sponsor
- Mikrobiomik
- Start
- Oct 2024
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of MBK-01 in diverticulitis (3 arms), sponsored by Mikrobiomik. Planned start Oct 2024; status: authorised.
02
Drugs
MBK-01
03
Conditions
diverticulitis
Beyond the preview
Go deeper on 2023-506224-87-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506224-87-00.